Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC
Description
touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY
Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms
In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients.
Course director
Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA
The clinical expert
Prof. Nicholas Girard, Institut Curie, Paris, France
Module 2: Bridging resistance gaps post–EGFR-TKI: Expanding NSCLC treatment beyond actionable targets
In this module, Professor Pasi Jänne and Dr Helena Yu discuss the evolving management of EGFR-mutant NSCLC after EGFR-TKI progression. They address challenges of unexplained resistance, review combination and ADC treatment approaches, and highlight key factors such as patient selection, safety and emerging biomarkers
Course director
Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA
The clinical expert
Dr Helena Yu, Memorial Sloan Kettering Cancer Center, New York, NY, USA
This touchPODCAST is for HCPs only.
This activity is funded by an educational grant from AstraZeneca Ltd.
This medical education is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.
For further information visit our website:
https://touchoncologyime.org/egfr-tki-resistance-strategies-nsclc/
https://touchrespiratoryime.org/egfr-tki-resistance-strategies-nsclc/
United States
